UNSPSC 51432810: Lisinopril dihydrate

This classification denotes an ace inhibitor with the molecular formula C21H31N3O5.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7199S1YWR, chemically known as l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-, dihydrate, (s)- but more generally known as lisinopril, which bears US NIH Compound Identifier 5362118. European Medicines Agency schedules Lisinopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08533MIG.

UNSPSC 51432810 Lisinopril dihydrate, a Commodity code, covers specific pharmaceutical formulations procured by state and local public health and emergency services agencies. State and local governments buy lisinopril and other branded or generic antihypertensive medications under this code primarily to support emergency medical services, public health clinics, and intergovernmental pharmacy benefit programs. The issuing bodies span city fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating state and local jurisdictions.

Recent activity shows geographic spread across Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue, with a due date of April 8, 2026 and an estimated contract value of $40,000.00; the solicitation required four specific medication line items with nine-month minimum shelf life and firm pricing including all shipping costs, with a one-year contract term and options to renew for two additional years plus three 30-day extensions. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capacity and negotiated net pricing models independent of pharmacy benefit managers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed to participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; MMCAP requires vendors to maintain relationships with at least two of three authorized wholesalers and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.